BMC Nephrology最新文献

{"title":"Diagnostic value of the urea-to-creatinine ratio for gastrointestinal bleeding source: influence of renal function.","authors":"Philipp Russ, Julian M Koppenhöfer, Simon Bedenbender, Thomas S Tarawneh, Ulrike W Denzer, Ivica Grgic, Martin Rußwurm, Christian S Haas","doi":"10.1186/s12882-025-04382-y","DOIUrl":"10.1186/s12882-025-04382-y","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"464"},"PeriodicalIF":2.4,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12359887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of tacrolimus in the treatment of Henoch-Schönlein purpura nephritis: systematic review and meta-analysis.","authors":"Tong Xie, Yan Ding, Fan Liu","doi":"10.1186/s12882-025-04353-3","DOIUrl":"10.1186/s12882-025-04353-3","url":null,"abstract":"<p><strong>Background: </strong>Henoch-Schönlein purpura nephritis (HSPN) is the most severe manifestation of Henoch-Schönlein purpura, significantly impacting patient outcomes. While immunosuppressive therapies like cyclophosphamide (CTX) and mycophenolate mofetil (MMF) are commonly used, evidence regarding the efficacy and safety of tacrolimus (TAC) in HSPN remains limited. This study presents the first systematic review and meta-analysis specifically evaluating the efficacy and safety of tacrolimus (TAC) in treating Henoch-Schönlein purpura nephritis (HSPN), aiming to fill a critical gap in evidence for clinical decision-making.</p><p><strong>Methods: </strong>This systematic review and meta-analysis, the first focused specifically on TAC in HSPN, included seven studies comprising 727 patients. A comprehensive search was conducted across multiple databases, including the Cochrane Library, PubMed, Embase, Medline, Web of Science, CNKI, Wanfang, SinoMed, VIP, and Embase. Studies comparing TAC with control treatments, such as CTX or MMF, in HSPN patients were included. Odds ratios (ORs) were calculated for dichotomous outcomes, while standardized mean differences (SMDs) with 95% confidence intervals (CIs) were used for continuous variables. Depending on heterogeneity, either random-effects or fixed-effects models were applied. Data synthesis was performed using RevMan software.</p><p><strong>Results: </strong>A total of seven studies were included. TAC therapy significantly improved clinical efficacy in HSPN patients (OR = 4.43; 95% CI: 2.86-6.87; P < 0.001). Additionally, TAC significantly reduced urine protein levels (SMD = -1.17; 95% CI: -1.83 to -0.51; P < 0.001), serum creatinine (Scr) (SMD = -2.33; 95% CI: -3.00 to -1.65; P < 0.001), and blood urea nitrogen (BUN) (SMD = -1.49; 95% CI: -1.94 to -1.04; P < 0.001). Importantly, there were no significant differences in the incidence of adverse events between the TAC and control groups.</p><p><strong>Conclusion: </strong>This is the first systematic review and meta-analysis specifically evaluating TAC in HSPN, providing novel evidence that TAC is an effective and safe therapeutic option for these patients. Its potential advantages over conventional immunosuppressive therapies highlight the need for further high-quality, long-term randomized controlled trials to confirm these findings and establish TAC's role in HSPN management.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"463"},"PeriodicalIF":2.4,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12359974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meprin β activity modulates cellular proliferation via trans-signaling IL-6-mediated AKT/ERK pathway in IR-induced kidney injury.","authors":"Shaymaa Abousaad, Faihaa Ahmed, Ayman Abouzeid, Christine Adhiambo, Elimelda Moige Ongeri","doi":"10.1186/s12882-025-04224-x","DOIUrl":"10.1186/s12882-025-04224-x","url":null,"abstract":"<p><strong>Background: </strong>Inflammation plays a central role in the progression of kidney injury induced by ischemia/reperfusion (IR). Meprin metalloproteinases have been implicated in the pathophysiology of IR-induced kidney injury. Existing data from in vitro and in vivo studies show that meprins modulate interleukin-6 (IL-6)-mediated inflammation via proteolytic processing of IL-6 and its receptor. IL-6 trans-signaling induces proliferation through either Mitogen-activated protein kinase /extracellular signal-regulated kinase (MAPK/ERK) or Phosphatidylinositol 3-Kinase/ protein kinase B (PI3K/AKT) pathway or in crosstalk with AKT/ERK. We previously showed that meprin β modulates cellular survival B-Cell Lymphoma/Leukemia 2 (BCL-2) through IL-6/Janus kinase/ Signal Transducer and Activator of Transcription (IL-6/JAK/STAT) signaling pathway in IR-induced kidney injury. However, it's not known how meprin β modulation of the IL-6 signaling pathway impacts the cellular proliferation in IR-induced acute kidney injury. The goal of the current study was to determine how meprin β modulation of the IL-6 signaling pathway impacts downstream cellular proliferation in IR-induced kidney injury.</p><p><strong>Methods: </strong>We induced Ischemia/Reperfusion injury with unilateral IR as a model of renal inflammation in wild-type (WT) and meprin β knockout (βKO) mice, with the contralateral kidneys serving as controls. The mice were sacrificed at 96 h post-IR, and kidney tissue processed for evaluation by RT-PCR and immunohistochemistry. Statistical analysis utilized two-way ANOVA.</p><p><strong>Results: </strong>RT-PCR data showed a significant increase in mRNA levels for IL-6 and proliferating cell nuclear antigen (PCNA) in WT and βKO mice at 96 h-post IR when compared to WT control kidneys. However, the baseline mRNA levels for PCNA were significantly higher in βKO when compared to WT kidneys. Immunohistochemical data showed significant increases in IL-6, PCNA, p-AKT and p-ERK in select tubules in both genotypes at 96 h post-IR when compared to control kidneys for each genotype. Data from immunofluorescence counterstaining of kidney tissues revealed that at 96 hours post-IR, IL-6, PCNA, p-AKT, and p-ERK were primarily expressed in meprin β-expressing proximal tubules (PTs), where meprins are abundantly present. However, high levels of IL-6 were also present in the lumen of PTs and DTs from WT and βKO kidneys at 96 h post-IR, suggesting increased release/shedding into filtrate and subsequently into urine.</p><p><strong>Conclusion: </strong>In conclusion, this study highlights the role of meprin β activity in regulating cellular proliferation through PCNA regulation, driven by the IL-6-mediated AKT/ERK signaling pathway during the recovery phase following IR-induced kidney injury.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"467"},"PeriodicalIF":2.4,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How does LAMB2 contribute to kidney disease? Insights from a pediatric case.","authors":"I Trutin, L Oletić, D Galešić Ljubanović, D Krgović, Tamara Nikuševa Martić","doi":"10.1186/s12882-025-04396-6","DOIUrl":"10.1186/s12882-025-04396-6","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"465"},"PeriodicalIF":2.4,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12359885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial.","authors":"Amira Reda Muhammad Galal, Nahla Mohamed Teama, Karema Abu-Elfotuha, Ahmed D Alatawi, Hanan Alshareef, Ahmed M E Hamdan, Ahmed Aljabri, Mohannad Alshibani, Zeinab AlKasaby Mahmoud Zalat","doi":"10.1186/s12882-025-04399-3","DOIUrl":"10.1186/s12882-025-04399-3","url":null,"abstract":"<p><strong>Background/objectives: </strong>Chronic kidney disease (CKD) is a highly prevalent, irreversible, and progressive disease associated with a high cardiovascular risk. We aimed to clinically investigate the extra-therapeutic effect of adding therapeutic doses of pentoxifylline (PTX) and/or folic acid (FA) for CKD patients to the standard care on their health-related quality.</p><p><strong>Methods: </strong>A randomized, prospective, parallel, and controlled clinical trial of CONSORT 80 patients diagnosed with CKD stages 3-5 were stratified by simple randomization into four groups (20 patient/group) and followed up for 6 months.</p><p><strong>Control group: </strong>received standard usual care therapy only; PTX group: received therapeutic dose of PTX added to standard usual care therapy; FA group: received FA added to standard usual care therapy; and PTX and FA group: received both PTX and FA added to their standard usual care therapy. The primary objective was to compare the renal function biochemical parameters for the intervention groups compared to the control group. Meanwhile, the secondary objective was to compare the incidence of readmission to hospitalization with cardiovascular events, incidence of peripheral vascular diseases and Fatigue Assessment Scale (FAS) for the intervention groups compared to the control group.</p><p><strong>Clinical trial registration: </strong>This study's research was granted authorization by the Research Ethics Committee (REC), Faculty of Medicine, Ain Shams University, No. (FMASU MS UNIV 15/2022) dated to 15/12/2022, and the Ethical Committee in the Faculty of Pharmacy (Girls), Al-Azhar University, No. (313) dated to 22/12/2022. This study was authorized by https://clinicaltrials.gov/ (NCT05284656) and the first date of registration was 16/02/2022. All patients were assigned to write an informed consent.</p><p><strong>Results: </strong>There was a significant improvement in renal function biochemical parameters and a significant reduction in the FAS for the intervention groups compared to the control group.</p><p><strong>Conclusions: </strong>Our results demonstrated that administration of therapeutic doses of PTX and/or FA in CKD patients delayed the progression of advanced chronic kidney disease and has been used successfully improved their health-related quality of life.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"468"},"PeriodicalIF":2.4,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UK Kidney Association Clinical Practice Guideline on vascular access for haemodialysis.","authors":"Emma Aitken, Hameed Anijeet, Damien Ashby, Wayne Barrow, Francis Calder, Brett Dowds, Catherine Fielding, James Gilbert, Rob Jones, Narayan Karunanithy, Zaib Khawaja, Emma Roberts, Mike Robson, Rukshana Shroff, Hannah Stacey, Peter Thomson, Dan Waters","doi":"10.1186/s12882-025-04374-y","DOIUrl":"10.1186/s12882-025-04374-y","url":null,"abstract":"&lt;p&gt;&lt;p&gt;This guideline is written primarily for doctors and nurses working in dialysis centres and related areas of medicine in the UK, and is an update of a previous version written in 2015. It aims to provide guidance on how to provide vascular access care for patients approaching and undergoing haemodialysis, and provides a standard of care which centres should in general aim to achieve. We would not advise patients to interpret the guideline as a rulebook, but perhaps to answer the question: \"What does good quality vascular access care look like?\". The guideline is split into sections: each begins with a few statements which are graded by strength (1 is a firm recommendation, 2 is more like a sensible suggestion), and the type of research available to back up the statement, ranging from A (good quality trials so we are pretty sure this is right) to D (more like the opinion of experts than known for sure). After the statements there is a short summary explaining why we think this, often including a discussion of some of the most helpful research. There is then a list of the most important medical articles so that you can read further if you want to - most of this is freely available online, at least in summary form. A few notes on the individual sections: 1.  This section covers key concepts relevant to vascular access and focusses on access type selection, including a historical introduction and review of the key literature informing our understanding. This explains why we are moving away from the outdated advice in previous guidelines (e.g. that 'all patients should dialyse with a fistula as first choice') towards a process which treats dialysis access selection as a choice, respecting patient individuality, aiming to provide high quality assessment and advice, so that patients are supported in making informed decisions. The basic concept of the fistula as optimal access is highlighted and remains valid, but it is placed within a more modern concept of care, in which the patient is at the centre of the decision process. 2.  This section addresses the initial planning of access, from education and vein preservation, through to the timing of assessment and access formation, emphasising in particular the need to plan ahead. 3.  This section deals with the formation and routine care of AV access (fistulas and grafts), covering access type and configuration, surgical and anaesthetic technique, the maturation period (before a fistula is ready to be used), and initiation and maintenance of optimal cannulation (needling). 4.  This section deals with some of the complications of AV access. Research in this area is ongoing and not yet sufficient to give clear guidance, so we emphasise again the importance of involving patients in treatment decisions. 5.  This section deals with the placement and routine care of catheter access (lines), covering location, technique, anticoagulant locks, and regular exit site disinfection and dressings. 6.  This section d","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"461"},"PeriodicalIF":2.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in chronic kidney disease mortality among patients with systemic lupus erythematosus: a U.S. population-based study (1999-2020).","authors":"Maria Qadri, Shafiq Ur Rahman, Hammad Javaid, Kritick Bhandari, Rahman Syed, Ameer Afzal Khan, Zaryab Bacha, Rizwana Noor, Maryem Filal","doi":"10.1186/s12882-025-04394-8","DOIUrl":"10.1186/s12882-025-04394-8","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"462"},"PeriodicalIF":2.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Identifying and integrating consumer-prioritised topics and outcomes in clinical practice guidelines on managing kidney stones.","authors":"David J Tunnicliffe, Ieuan Wickham, Allison Jauré, Brydee Johnston, Andrew J Mallett, Adam Mullan, Lyn Lloyd, Nicole Scholes-Roberston, Hicham Cheikh Hassan, Matthew Jose","doi":"10.1186/s12882-025-04365-z","DOIUrl":"10.1186/s12882-025-04365-z","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"456"},"PeriodicalIF":2.4,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and risk factors of post-transplant diabetes mellitus among kidney transplant recipients: a retrospective study from a tertiary center in Saudi Arabia.","authors":"Mutlaq Alotaibi, Najlaa Almalki, Manal E Alotaibi, Majed Alosaimi, Monther Alazwari, Mohamed Hussein, Faisal Alhomayani, Abdulmajeed Alotaibi, Ameerah Bajaber, Fahad Bhutto, Abdulmajeed Algethami, Bassem A Almalki","doi":"10.1186/s12882-025-04375-x","DOIUrl":"10.1186/s12882-025-04375-x","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"460"},"PeriodicalIF":2.4,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between intra-bladder pressure and acute kidney injury in patients with acute pancreatitis: interpretable machine learning approach.","authors":"Gang Liao, Baning Ye, Jianquan Li, Mingxiang Wen","doi":"10.1186/s12882-025-04371-1","DOIUrl":"10.1186/s12882-025-04371-1","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"459"},"PeriodicalIF":2.4,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}